Forge Biologics announces updated positive clinical data in RESKUE, a new phase 1/2 gene therapy study for patients with Krabbe disease

Maria Escolar, MD, chief medical officer, Forge Biologics (Photo: Business Wire)

business wire

Forge Biologics, the contracting gene therapy development and manufacturing organization, today announced that Chief Medical Officer Maria Escolar, MD, MS, updated clinical data from the Rescue Phase 1/2 clinical trial for the company’s new gene therapy FBX-101. Will present. For the treatment of patients with Krabbe disease during the 29th Congress of the European Society of Gene and Cell Therapy (ESGCT) in Edinburgh, Scotland, from 11-14 October 2022.

This press release contains multimedia content. Watch the full release here:

Maria Escolar, MD, chief medical officer, Forge Biologics (Photo: Business Wire)

The original text of this declaration, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.

media inquiries

marina corletto

Senior Manager, Marketing and Communications

[email protected]

Requests for information from families and doctors

Maria Escolar, MD

chief Medical Officer

[email protected]

investor relations

Christina Perri

Senior Vice President, Finance and Investor Relations

[email protected]

business development

magdalena tyrpion

Senior Vice President, Head of Business Development

[email protected]

permanent link:

Press Release – Business Wire Editorial Responsibility

Please enter your comment!
Please enter your name here